

























All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 2	
Summary		
Understanding	 the	 circuits	 that	 promote	 an	 efficient	 resolution	 of	 inflammation	 is	 crucial	 to	
deciphering	 the	molecular	 and	 cellular	 processes	 required	 to	 promote	 tissue	 repair.	Macrophages	
play	 a	 central	 role	 in	 the	 regulation	 of	 inflammation,	 resolution	 and	 repair/regeneration.	 Using	 a	
model	 of	 skeletal	 muscle	 injury	 and	 repair,	 herein	 we	 identify	 Annexin	 A1	 (AnxA1)	 as	 the	
extracellular	trigger	of	macrophage	skewing	towards	a	pro-reparative	phenotype.	Brought	 into	the	
injured	tissue	initially	by	migrated	neutrophils,	and	then	over-expressed	in	infiltrating	macrophages,	
AnxA1	 activates	 FPR2/ALX	 receptors	 and	 the	 downstream	 AMPK	 signalling	 cascade	 leading	 to	
macrophage	 skewing,	dampening	of	 inflammation	and	 regeneration	of	muscle	 fibres.	Mice	 lacking	
AnxA1	 in	 all	 cells	 or	 in	 myeloid	 cells	 only	 display	 a	 defect	 in	 this	 reparative	 process.	 In	 vitro	
experiments	 recapitulated	 these	properties,	with	AMPK	null	macrophages	 lacking	AnxA1-mediated	
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a	 multitude	 of	 pathologies,	 from	 arthritis	 to	 sepsis	 to	 dementia	 (Perretti	 et	 al.,	 2015;	 Tabas	 and	
Glass,	2013).		
	





progression	 of	 an	 inflammatory	 response,	 acting	 to	 clear	 pathogens,	 effete	 cells	 and	 debris	 by	
phagocytosis	(Mantovani	et	al.,	2013),	serving	as	antigen	presenting	cells	to	recruit	the	adaptive	arm	
of	 the	 immune	 response	 (Motwani	 and	Gilroy,	 2015),	 and	 ultimately	 enabling	 processes	 of	 tissue	
repair	and	resolution	(Lucas	et	al.,	2010;	Troidl	et	al.,	2009).	That	one	cell	type	is	able	to	achieve	this	
diverse	 array	of	 functions	 is	 due	 in	 large	part	 to	 their	 remarkable	degree	of	 phenotypic	plasticity,	
with	macrophages	existing	in	a	wide	variety	of	forms	along	a	spectrum	running	from	a	largely	pro-
inflammatory	 state,	 often	 indicated	 as	 M1,	 to	 a	 primarily	 non-phlogistic	 and	 pro-resolving	
phenotype,	termed	M2	(Murray	et	al.,	2014).		
	
A	 number	 of	 factors	 promoting	 this	 phenotypic	 transformation	 have	 been	 studied	 including	
exposure	 to	 anti-inflammatory	 cytokines	 such	 as	 interleukin	 (IL)-10	 and	 IL-4,	 and	 the	 phagocytic	
removal	 of	 cell	 debris,	 although	 a	 complete	 description	 of	 the	 underlying	 mechanisms	 is	 lacking	
(Martinez	and	Gordon,	2014).	We	and	others	have	identified	a	key	role	for	the	intracellular	signalling	
pathway	governed	by	AMP-activated	protein	kinase	(AMPK)	(Chan	et	al.,	2015;	Mounier	et	al.,	2013;	
Park	 et	 al.,	 2017).	 Activation	 of	 this	 pathway	 is	 required	 for	 efficient	 conversion	 of	 pro-	 to	 anti-
inflammatory-type	macrophages,	and	inhibition	of	such	a	response	significantly	attenuated	recovery	
in	 a	 model	 of	 inflammatory	 skeletal	 muscle	 injury	 (Mounier	 et	 al.,	 2013).	 Whilst	 AMPK	 is	
undoubtedly	 important	 in	 the	 phenotypic	 conversion	 of	 macrophages	 during	 the	 course	 of	 an	
inflammatory	reaction,	the	nature	of	the	extracellular	trigger(s)	for	its	stimulation	remain	unclear.		
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The	protein	annexin	A1	(ANXA1)	 (Lim	and	Pervaiz,	2007;	Perretti	and	D'Acquisto,	2009),	 is	a	major	
driver	 of	 inflammatory	 resolution,	 promoting	 neutrophil	 apoptosis	 (Solito	 et	 al.,	 2003),	 non-
phlogistic	monocyte	recruitment	(McArthur	et	al.,	2015)	and	macrophage	efferocytosis	(Dalli	et	al.,	
2012;	 Scannell	 et	 al.,	 2007).	 Moreover,	 we	 and	 others	 have	 recently	 provided	 evidence	 showing	
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Fig	 1B-C),	 the	proportion	of	macrophages	 expressing	 its	 primary	 receptor,	 Fpr2/3,	 decreased	over	
time,	from	approximately	95%	at	day	2	to	70%	at	day	7	and	just	5%	two	weeks	post-lesioning,	even	
though	 significant	 numbers	 of	 macrophages	 were	 still	 detected	 in	 the	 tissue	 (Suppl	 Fig	 2A-B).	




(Fig	 1A-B,	 Suppl	 Fig	 3A),	 recovery	 of	 muscle	 mass	 following	 administration	 of	 cardiotoxin	 was	
significantly	 reduced	 in	 AnxA1-/-	 and	 Fpr2/3-/-	mice	 than	 in	wild-type	 animals	 (Fig	 1B).	 Histological	
analysis	of	muscles	28	days	post-injury	revealed	significantly	reduced	myofiber	cross-sectional	area	




approximately	 60%	 of	 macrophages	 expressed	 a	 pro-resolving,	 anti-inflammatory	 phenotype	
(CD45+Ly6C/GnegF4/80hi)	in	wild-type	mice,	whilst	AnxA1-/-	and	Fpr2/3-/-	animals	showed	comparable	
levels	of	pro-	 (CD45+Ly6C/GhiF4/80low)	 and	anti-inflammatory	 (CD45+Ly6C/GlowF4/80hi)	 cells	 (Fig	1G,	
Suppl	Fig	3B).	Consequently,	the	resolution	 index	(ratio	of	anti-	to	pro-inflammatory	macrophages)	
of	AnxA1-/-	and	Fpr2/3-/-	mice	was	significantly	 lower	than	that	of	wild-type	animals,	 indicative	of	a	
prolonged	 inflammatory	 response	 (Fig	 1H).	 These	 results	 indicate	 that	 a	 proportion	 of	 pro-
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 6	





important	 regulatory	 functions	 for	 this	 pathway	 in	 skeletal	 muscle	 injury.	 However,	 while	 Fpr2/3	




marrow-derived	 leukocytes.	 Therefore,	 CX3CR1-GFP	 mice,	 which	 harbour	 GFP-expressing	
monocytes/macrophages	were	irradiated	and	transplanted	with	wild-type	or	AnxA1-/-	derived	bone	











pro-inflammatory	 to	 a	 pro-resolving/reparative	 phenotype,	 we	 investigated	 these	 effects	 in	 vitro	
using	human	PBMC-derived	macrophages.	An	M1-like	macrophage	phenotype	was	induced	by	24	h	
incubation	with	bacterial	lipopolysaccharide	(LPS)	and	γ-interferon	(IFNγ),	prior	to	addition	of	human	
recombinant	 ANXA1	 (hrANXA1).	 Following	 hrANXA1	 treatment,	 analysis	 of	 cell	 surface	 markers	
revealed	 a	 significant	 reduction	 in	 expression	 of	 the	M1	marker	 protein	major	 histocompatibility	
complex	 II	 (MHCII)	 (Fig	3A),	accompanied	by	a	significant	 increase	 in	expression	of	 the	M2	marker	
protein	 CD206	 (Fig	 3B).	 These	 surface	 marker	 changes	 were	 mirrored	 by	 changes	 at	 the	
transcriptional	level,	with	hrANXA1	treatment	inducing	a	reduction	in	mRNA	expression	for	the	pro-
inflammatory	species	Tnfa	and	Nos2	paired	with	increased	message	of	Il-10	(Fig.	3C-E).	No	significant	
changes	 in	Tgfb1	expression	were	quantified	 (Fig.	3F).	Together,	 these	 in	vitro	data	support	our	 in	
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vivo	 findings,	 providing	 evidence	 that	 ANXA1	 application	 favours	 a	 pro-resolving	 macrophage	
phenotype.		
	
The	 specificity	 of	 hrANXA1	 action	 through	 its	 human	 receptor	 FPR2/ALX	was	 then	determined,	 to	
complement	the	in	vivo	observations	made	with	Fpr2/3-/-	mice	lacking	the	orthologue	of	the	human	
FPR2/ALX	 (Dufton	 et	 al.,	 2010).	 Intriguingly,	 we	 observed	 significant	 FPR2/ALX	 surface	 expression	
both	 in	unstimulated	human	PBMC-derived	macrophages	and	M1-phenotype	cells,	yet	cell	 surface	
expression	of	 the	receptor	was	 lost	on	cells	stimulated	towards	an	M2	phenotype	with	 IL-4	 (Suppl	
Fig.	 4).	 These	 data	 are	 in	 agreement	 with	 the	 in	 vivo	 observation	 that	 Fpr2/3-/-	 is	 absent	 from	
macrophages	 that	 have	 infiltrated	 the	 injured	 muscle	 at	 Day	 7	 and	 beyond,	 that	 is,	 when	 a	
reparative	 cell	 phenotype	 has	 been	 acquired	 (Suppl	 Fig	 2B-C).	 The	 functional	 engagement	 of	
FPR2/ALX	 was	 then	 confirmed	 through	 use	 of	 the	 selective	 antagonist	 WRW4.	 The	 modulatory	




Together	 these	 experiments	 represent	 a	 clear	 in	 vitro	 counterpart	 to	 the	 effects	 observed	 in	 the	




The	 enzyme	 5'-adenosine	monophosphate-activated	 protein	 kinase,	 AMPK,	 plays	 a	 critical	 role	 in	
macrophage	 phenotype	 skewing	 and	 is	 necessary	 for	 efficient	 regeneration	 after	 skeletal	 muscle	




the	 AMPK	 signalling	 pathway,	 promoting	 phosphorylation	 of	 Ca2+/calmodulin-dependent	 protein	
kinase	II,	AMPKα1	itself	and	its	downstream	effector	acetyl-CoA	carboxylase	(Fig	4A-B).	Interestingly,	
the	 phosphorylation	 of	 these	 proteins	 in	 macrophages	 only	 occurred	 to	 an	 appreciable	 degree	
following	exposure	to	hrANXA1	for	30-60	min	(Fig	4B-D),	 in	contrast	to	early	MAP	kinase	signalling	
previously	 reported	 in	 human	 monocytes	 (McArthur	 et	 al.,	 2015).	 That	 activation	 of	 AMPKα1	
depended	upon	binding	of	hrANXA1	to	FPR2/ALX	was	confirmed	through	analysis	of	 the	effects	of	
the	 antagonist	 WRW4,	 which	 abrogated	 hrANXA1-evoked	 AMPKα1	 phosphorylation	 in	 human	
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macrophages	 (Fig	 4E).	Analyses	of	murine	bone	marrow-derived	macrophages	 from	wild-type	and	
Fpr2/3-/-	animals	confirmed	the	pivotal	role	of	this	receptor:	whilst	treatment	with	hrANXA1	induced	




We	 investigated	 the	 relationship	 between	 FPR2/ALX-mediated	 AMPK	 activation	 and	 the	 shift	 in	
macrophage	phenotype	induced	by	hrANXA1	treatment	through	analyses	in	primary	bone	marrow-
derived	macrophages	taken	from	wild-type	mice	and	animals	lacking	the	key	catalytic	α1	subunit	of	
AMPK	 (Jorgensen	 et	 al.,	 2005).	Whilst	 treatment	 of	wild-type	macrophages	with	 hrANXA1	 (10nM,	
24h)	reduced	the	percentage	of	macrophages	positive	 for	 the	pro-inflammatory	markers	 iNOS	and	
CCL3,	 this	 response	 was	 notably	 absent	 in	 cells	 from	 AMPKα1-/-	 mice	 (Fig	 5A).	 Correspondingly,	













Together,	 these	 data	 from	 human	 and	 mouse	 macrophages	 make	 a	 compelling	 case	 that	
macrophage	 phenotype	 shifting	 can	 be	 induced	 through	 an	 ANXA1/FPR2/AMPK	 cascade.	 To	
investigate	whether	this	process	underlies	differences	in	recovery	from	cardiotoxin-induced	muscle	
lesions	 seen	 between	 wild-type	 and	 AnxA1-/-	 and	 Fpr2/3-/-	 mice,	 we	 made	 use	 of	 an	 established	
model	of	in	vitro	muscle	repair	(Mounier	et	al.,	2013;	Varga	et	al.,	2016b).		
	
We	 employed	 an	 in	 vitro	model	 of	 adult	myogenesis	 in	which	 conditioned	medium	 from	 primary	
bone	 marrow-derived	 macrophages	 was	 used	 to	 stimulate	 primary	 murine	 myoblasts	 for	 72h,	
quantifying	 the	 proportion	 of	 multinucleated	 myotubes	 (Fig.	 5F).	 As	 such	 this	 in	 vitro	 setting	
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recapitulates	the	processes	of	adult	myogenesis	(activation,	differentiation,	migration	and	fusion	of	
muscle	 cells)	 that	 occur	 during	 skeletal	 muscle	 regeneration	 (Mounier	 et	 al.,	 2013;	 Varga	 et	 al.,	
2016b).	 Conditioned	medium	 from	 ANXA1-treated	wild-type	macrophages	 induced	 an	 increase	 in	
myotube	 fusion	 index	 (Fig	 5G-I).	 This	 response	 was	 absent	 when	 myotubes	 were	 treated	 with	
conditioned	medium	from	ANXA1-treated	AMPKα1-/-	macrophages	(Fig	5G-I).		
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Discussion	
The	 timely	 resolution	 of	 inflammation	 is	 a	 fundamental	 requirement	 for	 restoring	 homeostasis	
following	 infection	or	 damage,	with	 its	 failure	 being	 a	 significant	 contributory	 factor	 to	 numerous	
chronic	inflammatory	pathologies.	Macrophages	are	key	players	in	this	process,	given	their	ability	to	
transition	 from	generally	pro-inflammatory	 to	anti-inflammatory	phenotypes	 (Motwani	and	Gilroy,	
2015).	 Substantial	 effort	has	 gone	 into	deciphering	 the	 complex	 signals	underpinning	macrophage	
plasticity,	with	numerous	 soluble	mediators	having	been	 implicated	 (Martinez	and	Gordon,	2014),	
but	 the	 mechanistic	 link	 between	 these	 factors	 and	 changes	 in	 phenotype	 remains	 poorly	
understood	especially	when	 investigated	 in	 specific	 tissue-restricted	 settings.	 In	 the	current	 study,	
we	 have	 employed	 a	 well-characterised	 model	 of	 muscular	 injury	 and	 recovery	 (Mounier	 et	 al.,	
2013)	 to	 identify	 the	 ability	 of	 myeloid	 cell-derived	 ANXA1	 to	 promote	 an	 anti-inflammatory	
macrophage	phenotype,	promoting	resolution	and	tissue	repair.	Moreover,	we	show	the	actions	of	
this	protein	to	be	mediated	through	the	cell	surface	receptor	FPR2/ALX	and	consequent	activation	of	
the	 intracellular	 signalling	 molecule	 AMPK,	 mechanistically	 linking	 external	 and	 intracellular	 pro-
resolving	signals	governing	macrophage	phenotype.		
	




itself	 beginning	 to	 express	ANXA1	during	 tissue	 repair,	 as	 noted	 previously	 (Bizzarro	 et	 al.,	 2012),	
experiments	with	chimeric	mice	confirmed	that	the	most	important	source	of	the	protein	to	enable	
muscle	 repair	 remains	 the	 myeloid	 cells	 themselves.	 While	 the	 current	 studies	 do	 not	 permit	
conclusive	 determination	 of	 whether	 neutrophils	 or	 macrophages	 are	 the	 primary	 source	 of	
endogenous	 ANXA1	 in	 the	 injured	 tissue,	 neutrophils	 contain	 substantial	 quantities	 of	 ANXA1	
(Francis	 et	 al.,	 1992),	which	we	 have	 previously	 shown	 to	 be	 a	major	monocyte	 chemoattractant	
(McArthur	et	al.,	2015)	suggesting	that	the	protein	-	produced	at	an	early	stage	by	and	released	from	
infiltrating	neutrophils	(Damazo	et	al.,	2006)	-	may	act	to	both	recruit	monocytes	and	promote	a	pro-
resolving	 phenotype	 in	 resulting	 macrophages.	 Whatever	 the	 ultimate	 cellular	 source	 of	 ANXA1	
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Besides	highlighting	the	role	of	ANXA1	as	a	regulator	of	inflammatory	resolution	(Leoni	and	Nusrat,	
2016),	 these	new	data	add	 further	weight	 to	 the	 importance	of	 its	principal	 receptor	 FPR2/ALX	 in	
this	 process,	 identifying	 it	 as	 a	 conduit	 for	 induction	 of	 a	 pro-resolving	 macrophage	 phenotype	
through	AMPK	 activation.	 It	 is	 notable	 that	macrophage	 FPR2/ALX	 expression	 declined	 during	 the	








of	 cytokines	 (Amici	 et	 al.,	 2017).	 Notably	 however,	 a	 significant	 proportion	 of	 the	 soluble	 pro-
resolving	 mediators	 so	 far	 identified	 derive	 from	 the	 adaptive	 arm	 of	 the	 immune	 response,	
particularly	 from	 TH2	 lymphocytes	 (Martinez	 and	 Gordon,	 2014).	 Our	 data	 however,	 highlight	 the	
ability	 of	 signalling	 components	 derived	 from	 the	 innate	 side	 of	 the	 immune	 system	 to	 promote	
resolution	in	the	absence	of	significant	activation	of	adaptive	mechanisms.	Moreover,	these	results	




Our	 data	 are	 the	 first	 to	 associate	 activation	 of	 FPR2/ALX	 and	 the	 major	 regulator	 of	 cellular	
metabolism,	AMPK,	showing	the	central	involvement	of	FPR2/ALX-stimulated	AMPK	activation	in	the	
induction	of	a	pro-resolving	macrophage	phenotype.	The	precise	mechanism	linking	AMPK	activation	
with	a	change	 in	phenotype	 is	as	yet	unclear,	but	 there	 is	 increasing	evidence	 that	changes	 in	 the	
metabolic	status	of	 immune	cells	can	affect	their	 inflammatory	activity	(O'Neill	et	al.,	2016;	Pearce	
and	 Pearce,	 2013).	 Pro-inflammatory	 dendritic	 cells	 and	 T	 lymphocytes	 are	 characterised	 by	 high	
levels	 of	 glycolysis,	 akin	 to	 the	Warburg	 shift	 described	 in	 cancer	 (Rodriguez-Prados	 et	 al.,	 2010),	
whereas	 immune	 cells	 with	 an	 anti-inflammatory	 or	 pro-resolving	 profile	 tend	 to	 exhibit	 greater	
mitochondrial	 respiration	 (Jha	 et	 al.,	 2015;	 Mounier	 et	 al.,	 2013;	 Tannahill	 et	 al.,	 2013).	 The	
mechanistic	 details	 of	 how	 such	 changes	 in	metabolic	 phenotype	 relate	 to	 immune	 function,	 and	
indeed	whether	these	differences	reflect	or	drive	immunophenotype	is	unclear	(Van	den	Bossche	et	
al.,	2017),	but	 it	 is	notable	 that	AMPK	 is	a	 significant	promoter	of	mitochondrial	 respiration	and	a	
regulator	 of	 glycolysis	 through	 the	 modulation	 of	 lactate	 dehydrogenase	 activity	 (Theret	 et	 al.,	
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phenotype	 most	 closely	 associated	 with	 anti-inflammatory	 macrophage	 activation,	 but	 this	
hypothesis	requires	further	investigation.	
	
AMPK	 is	 involved	 in	 different	 cellular	 mechanisms	 that	 regulate	 skeletal	 muscle	 homeostasis	
(Kjobsted	et	al.,	2018).	Our	previous	 findings	highlight	 the	 importance	of	crosstalk	between	AMPK	
and	 the	 mTOR	 signaling	 pathway	 for	 the	 control	 of	 muscle	 cell	 size	 in	 the	 adaptive	 response	 of	
skeletal	muscle	(Lantier	et	al.,	2014;	Lantier	et	al.,	2010;	Mounier	et	al.,	2011;	Mounier	et	al.,	2009).	
Moreover,	 we	 have	 recently	 shown	 that	 AMPKα1,	 activated	 following	 phagocytosis,	 is	 crucial	 for	
macrophage	skewing	from	a	pro-	to	an	anti-inflammatory	phenotype	during	resolution	(Mounier	et	
al.,	 2013),	 demonstrating	 that	 the	 CAMKKII/AMPKα1	 pathway	within	macrophages	 is	 required	 for	
proper	 and	 complete	 skeletal	 muscle	 regeneration.	 Anti-inflammatory	 macrophages	 promote	
myogenic	differentiation	and	fusion	(Saclier	et	al.,	2013a;	Saclier	et	al.,	2013b;	Varga	et	al.,	2016b),	a	
finding	of	importance	for	skeletal	muscle	muscle	regeneration	where	a	sequential	presence	of	pro-	
then	 anti-inflammatory	 cells	 is	 necessary	 for	 efficient	 regeneration	 process	 (Arnold	 et	 al.,	 2007;	
Varga	et	al.,	2013).	Therefore,	the	pro-resolving	effect	of	ANXA1-AMPK	signalling	in	macrophages	is	
likely	 to	 be	 beneficial	 for	 skeletal	 muscle	 regeneration,	 as	 suggested	 by	 the	 positive	 effect	 of	
conditioned	medium	from	ANXA1-treated	macrophages	on	adult	myogenesis	in	vitro.	
	
In	 summary,	 we	 present	 here	 a	 novel	 mechanism	 governing	 the	 conversion	 of	 pro-inflammatory	
macrophages	 to	 a	 pro-resolving	 phenotype,	 linking	 leukocyte-derived	 ANXA1,	 FPR2/ALX	 and	
intracellular	AMPK	activation.	This	 finding	reinforces	the	position	of	the	ANXA1-FPR2/ALX	pathway	
as	 a	 pivotal	 regulator	 of	 inflammatory	 resolution,	 and	 suggests	 that	 it	 may	 represent	 a	 suitable	
target	 for	 therapeutic	 exploitation	 for	 the	 innovative	 treatment	 of	 pathologies	 characterised	 by	
chronic,	non-resolving	inflammation.		
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SM,	 TG,	 GJ,	 JG,	 MT	 &	 RM	 performed	 TA	 lesion	 and	 analysis,	 GJ	 &	 RM	 produced	 and	 analyzed	
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(A)	 Experimental	 set-up.	 Acute	 injury	 was	 induced	 by	 cardiotoxin	 (CTX)	 injection	 in	 the	 Tibialis	
Anterior	(TA)	of	Wild-Type,	AnxA1-/-	and	Fpr2/3-/-	mice.	Muscles	were	analysed	0,	7	and	28	days	after	
injury.	(B)	TA	mass	normalised	to	mouse	body	weight.	(C)	Hematoxylin-eosin	(HE)	staining	of	muscles	
28	days	after	 injury.	White	bar	=	50	μm.	 (D-E)	Myofiber	cross-sectional	area	 (D),	number	of	nuclei	








sample	 after	 around	 5	 weeks.	 Then	 animals	 were	 injured	 in	 their	 Tibialis	 Anterior	 by	 cardiotoxin	
(CTX)	 injection	 and	muscles	 analysed	 0	 or	 28	days	 later.	 Engraftment	was	 confirmed	on	 the	bone	
marrow	of	each	animal	on	the	day	of	sacrifice.	(B-C)	Representative	FACS	plots	(B)	and	quantification	






like	 phenotype,	 prior	 to	 addition	 of	 human	 recombinant	 ANXA1	 (hrANXA1,	 10nM)	 for	 further	 6	
hours.	 (A-B)	 Mean	 Fluorescent	 Intensity	 (MFI)	 units	 measured	 by	 flow	 cytometry	 of	 MHCII	 pro-
inflammatory	 (A)	 and	 CD206	 anti-inflammatory	 (B)	 markers.	 Shown	 are	 MFI	 quantification	 (left	
panel)	and	representative	FACS	plots	(right	panel).	(C-F)	RT-qPCR	analysis	of	Tnfa	(C)	and	Nos-2	(D)	
pro-inflammatory	 genes,	 and	 Il-10	 (E)	 and	 Tgfb1	 (F)	 anti-inflammatory	 genes.	 (G-H)	 MFI	 units	 as	
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are	 representative	 blots	 (B)	 and	 quantification	 of	 pAMPKα1	 to	 AMPKα1	 (C)	 and	 pACC	 to	 ACC	 (D)	
ratios.	(E)	Representative	western	blot	(top	panel)	and	quantification	(bottom	panel)	of	pAMPKα1	to	
AMPKα1	 ratio	 in	 human	 PBMC-derived	 macrophages	 treated	 by	 hrANXA1	 in	 the	 presence	 or	
absence	 of	 10	µM	WRW4.	 (F)	 Representative	western	 blot	 (top	 panel)	 and	 quantification	 (bottom	
panel)	 of	 pAMPKα1	 to	 AMPKα1	 ratio	 in	 Wild-Type	 or	 Fpr2/3-/-	 murine	 bone	 marrow	 derived	




(A-B)	 Primary	 macrophages	 derived	 from	Wild-Type	 or	 AMPKα1-/-	 mice	 were	 treated	 with	 10nM	
hrANXA1	and	 the	percentage	of	 cells	expressing	 the	pro-inflammatory	markers	 iNOS	and	CCL3	 (A)	
and	 the	 anti-inflammatory	 markers	 TGFB1,	 CD163	 and	 CD206	 (B)	 was	 determined	 by	
immunofluorescence.	(C-E)	Human	PBMC-derived	macrophages	were	transfected	by	a	non-targeting	
or	 three	 different	 AMPKα1-targeting	 siRNAs	 and	 treated	with	 10	 nM	 hrANXA1	 for	 24	 h.	 AMPKα1	
protein	level	was	determined	by	western	blot	(C)	and	the	MFI	units	of	the	pro-inflammatory	MHCII	
(D)	and	anti-inflammatory	CD206	 (E)	markers	were	measured	by	 flow	cytometry.	 (F-I)	Conditioned	
medium	 produced	 by	 murine	 macrophages	 was	 transferred	 onto	 murine	 primary	 myoblasts	 and	
their	 fusion	 was	 measured	 by	 immunofluorescence.	 (F)	 Experimental	 set-up.	 (G)	 Representative	
images	of	desmin	(red)	and	Hoechst	(blue)	 labelling	of	myoblast	cultures.	White	bar	=	50	μm.	(H-I)	




Suppl	 Fig	 1.	 Related	 to	 Figure	 1.	 Immune	 cell	 recruitment	 and	 pattern	 of	 AnxA1	 expression	 in	
cardiotoxin-induced	muscle	injury	and	repair.	
Immunofluorescence	analysis	of	ANXA1	protein	 in	Tibialis	Anterior	muscle	after	 cardiotoxin	 injury.	
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Suppl	 Fig	 2.	Related	 to	 Figure	1.	 Immune	 cell	 recruitment	 and	 Fpr2/3	expression	 in	 cardiotoxin-
induced	muscle	injury	and	repair.	
Quantification	of	F4/80+	ANXA1+	cells	 in	Tibialis	Anterior	 (TA)	muscle	after	 cardiotoxin	 (CTX)	 injury	











Suppl	 Fig	 4.	 Related	 to	 Figure	 3.	 FPR2/ALX	 expression	 varies	 following	 human	 macrophage	
polarization.	
Human	 primary	 macrophages	 were	 polarised	 into	 M1	 or	 M2	 macrophages	 with	 IFNg	 and	 IL-4,	
respectively	(A-C)	Flow	cytometry	analysis	of	FPR2/ALX	expression.	Shown	are	representative	FACS	
plots	(A),	percentage	of	cells	expressing	FPR2/ALX	(B)	and	FPR2/ALX	MFI	(C).	(D)	RT-qPCR	analysis	of	
FPR2/ALX	mRNA	 level.	Results	 are	means	+/-	 SEM	of	 at	 least	 four	 independent	experiments.	 *p	<	
0.05	versus	M0	(non-activated).	
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in	 compliance	 with	 European	 legislation	 in	 France.	 Animal	 facilities	 are	 fully	 licensed	 by	 relevant	













TOF/TOF	 analysis.	 Endotoxin	 was	 determined	 with	 the	 Endosafe-PTS	 (FDA-licensed	 LAL	 cartridge	











Bone	 marrow-derived	 macrophages	 (BMDMs)	 were	 prepared	 from	 adult	 male	 wild-type	
sv129/C57Bl6	and	Prkaa1-/-	mice	(referred	to	as	AMPKα1-/-	(Jorgensen	et	al.,	2005)).	Mice	were	killed	
by	 cervical	 dislocation	 under	 isofluorane	 anaesthesia,	 and	 marrow	 was	 flushed	 from	 tibiae	 and	
femurs.	 Cells	were	plated,	washed	and	 grown	 for	 6-7	days	 in	DMEM	High	Glucose	High	Pyruvate,	
20%	 heat	 inactivated	 fetal	 calf	 serum	 (ThermoFisher),	 30%	 L929-cell	 conditioned	 medium,	 1%	
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Amphotericin	 B	 (2.5	 µg/ml,	 ThermoFisher)	 and	 100	 μg/ml	 streptomycin	 (ThermoFisher).	 For	
phenotypic	characterisation,	BMDMs	were	fixed	for	10	minutes	in	4%	formaldehyde,	permeabilized	
for	10	minutes	in	PBS	with	0.5	%	Triton	X-100	and	blocked	for	1	hour	in	PBS	with	4	%	BSA.	They	were	
then	 labeled	 overnight	 at	 4°C	 with	 anti-NOS2	 (#ab15323,	 Abcam),	 anti-CCL3	 (#ab32609,	 Abcam),	
anti-TGFβ1	 (#ab64715,	 Abcam),	 anti-CD163	 (#sc-20066,	 Santa-Cruz)	 and	 anti-CD206	 (#sc-58987,	
Santa-Cruz),	 followed	 by	 incubation	 for	 1	 hour	 at	 37°C	 with	 FITC-	 or	 Cy3-conjugated	 secondary	
antibodies	(Jackson	Immunoresearch	Inc).	Cells	were	stained	with	Hoechst	(Sigma)	and	mounted	in	





containing	20%	FBS	and	30%	conditioned	medium	of	 L929	 cell	 line	 (enriched	 in	CSF-1)	 for	7	days.	
Macrophages	 were	 activated	 with	 human	 recombinant	 annexin	 A1	 for	 3	 days	 (10	 nM)	 in	 DMEM	
containing	 10%	 FBS.	 After	 the	 washing	 steps,	 serum-free	 DMEM	 was	 added	 for	 24	 hr	 to	 obtain	
macrophage-conditioned	medium.	Murine	myogenic	precursor	cells	(MPCs)	were	obtained	from	TA	
muscle	 and	 cultured	 using	 standard	 conditions	 in	 DMEM/F12	 medium	 (Gibco	 Life	 Technologies)	
containing	20%	heat	inactivated	Foetal	Bovine	Serum	(FBS)	and	2%	G/Ultroser	(Pall	Inc).	MPCs	were	
seeded	 at	 30,000	 cell/cm2	 on	 Matrigel	 (diluted	 1:10)	 and	 incubated	 for	 3	 days	 with	 conditioned	
medium	containing	2%	heat	inactivated	horse	serum.	Cells	were	then	incubated	with	an	anti-desmin	
antibody	 (#ab32362,	 Abcam),	 followed	 by	 a	 Cy3-conjugated	 secondary	 antibody	 (Jackson	
Immunoresearch	 Inc)	 (Mounier	 et	 al,	 2013;	 Varga	 et	 al,	 2016).	 Cells	 were	 stained	 with	 Hoechst	






week-old	 recipient	 CX3CR1-GFP+/-	 males	 (monocytes/macrophages	 expressing	 GFP)	 previously	




blood	5	weeks	after	 the	 transplantation	and	on	bone	marrow	when	mice	were	 sacrificed	by	FACS	
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analysis.	 Briefly,	 red	 cells	 were	 lysed	 with	 ACK	 buffer	 and	 leukocytes	 were	 incubated	 with	 FcR	
Blocking	 Reagent	 (Miltenyi	 Biotec)	 for	 20	 min	 at	 4°C.	 Finally,	 cells	 were	 labeled	 with	 an	 APC-





Human	 cells	 were	 prepared	 according	 to	 an	 approved	 protocol	 (East	 London	 &	 the	 City	 Local	
Research	 Ethics	 Committee;	 no.	 06/Q605/40;	 P/00/029).	 Peripheral	 blood	 was	 collected	 from	
healthy	 volunteers	 by	 intravenous	 withdrawal	 in	 3.2%	 sodium	 citrate	 solution	 (1:10).	 Peripheral	






For	histological	analysis,	muscles	were	harvested,	snap	 frozen	 in	 liquid	nitrogen-chilled	 isopentane	
and	kept	at	-80°C	until	use.	Cryosections	(10µm)	were	prepared	for	hematoxylin-eosin	(HE)	or	Sudan	
Black	 staining.	 Fluorescence	 immunohistochemical	 analysis	 was	 performed	 according	 to	 standard	
procedures.	 Briefly,	 transverse	muscle	 cryosections	 (10	 µm)	were	 post-fixed	 by	 incubation	 for	 15	
minutes	in	4%	formaldehyde,	blocked	and	immunostained	using	primary	antibodies	directed	against	
Ly6G	 (1:100;	 #127602,	 Biolegend),	 F4/80	 (1:200,	 #123102,	 Biolegend)	 ANXA1	 (1:1,000;	 #71-3400,	
ThermoFisher)	 or	 Fpr2/3	 (1:100,	 #sc-18191-R,	 SantaCruz).	 Secondary	 antibodies	 were	 Alexa	 Fluor	
488-	 or	 594-conjugated	 goat	 anti-rabbit	 or	 anti-rat	 IgG	 (1:300;	 Invitrogen).	 Sections	 were	
counterstained	 with	 DAPI,	 mounted	 and	 examined	 using	 a	 TCS	 SP5	 confocal	 laser	 scanning	
microscope	(Leica	Microsystems)	fitted	with	405	nm,	488	nm	and	594	nm	lasers,	and	attached	to	a	
Leica	 DMI6000CS	 inverted	 microscope	 fitted	 with	 a	 40×	 objective	 lens	 (NA	 0.75	 mm;	 working	





cells	 were	 isolated	 from	 regenerating	 muscle	 TA	 using	 magnetic	 beads	 conjugated	 to	 anti-CD45	
antibody	 (Milteny	 Biotec)	 and	 then	 incubated	 with	 Fc-block	 (Milteny	 Biotec)	 for	 30	 min	 at	 4°C.	
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Finally,	 CD45+	 cells	 were	 stained	 with	 antibody	 against	 Ly-6C/G	 (#17-5931-82,	 eBioscience)	 and	
against	 F4/80	 (#12-4801-82,	 eBioscience).	 Percentages	 of	 Ly-6C/GhiF4/80low	 and	 Ly-6C/GnegF4/80hi	
cells	 were	 calculated	 among	 total	 F4/80pos	 cells	 following	 analysis	 by	 flow	 cytometry	 with	 a	




Primary	 human	 PBMC-derived	 macrophages	 were	 transfected	 with	 one	 of	 three	 different	
commercial	 siRNA	 sequences	 designed	 to	 target	 AMPKα1	 or	 an	 Allstars	 negative	 control	 siRNA	
sequence	 using	 Hiperfect	 transfection	 reagent	 according	 to	 the	manufacturer’s	 instructions	 (final	
concentration	2	nM;	all	Qiagen	GmbH,	Hilden,	Germany),	alongside	mock	transfected	cells.	After	48	
hours,	 cells	 were	 analysed	 for	 phenotypic	 conversion	 following	 hrANXA1	 treatment	 (6	 hours,	 10	
nM).	 A	 proportion	 of	 cells	 were	 analysed	 for	 AMPKα1	 expression	 by	 western	 blot	 using	 a	 rabbit	
polyclonal	 antibody	 raised	 against	 human	 the	 AMPKα1	 subunit	 (1:1,000,	 #2795,	 Cell	 Signalling	





anti-MHCII	 (#11-9956-42,	 Thermofisher)	 and	 APC-conjugated	mouse	monoclonal	 anti-CD206	 (#17-
2069-42,	Thermofisher)	or	isotype	controls	(all	Thermofisher)	according	to	manufacturer’s	protocols.	









Samples	 boiled	 in	 6×	 Laemmli	 buffer	 were	 subjected	 to	 standard	 SDS-PAGE	 (10%)	 and	
electrophoretically	 blotted	 onto	 Immobilon-P	 polyvinylidene	 difluoride	 membranes	 (Millipore,	
Watford,	 UK).	 Membranes	 were	 incubated	 with	 antibodies	 raised	 against	 human	 phospho-
Ca2+/calmodulin-dependent	 kinase	 (#12716,	 Cell	 Signalling	 Technology),	 phospho-AMPKα1	 (#2531,	
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Cell	 Signalling	 Technology),	 AMPKα1	 (#2795,	 Cell	 Signalling	 Technology),	 phospho-acetyl-CoA	




at	 10	 minute	 intervals;	 membranes	 were	 then	 incubated	 with	 secondary	 antibody	 (horseradish	


















All	 quantified	 in	 vitro	 data	 are	derived	 from	at	 least	 three	 independent	 donors,	with	 experiments	







All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.




Amici,	 S.A.,	 Dong,	 J.,	 and	 Guerau-de-Arellano,	 M.	 (2017).	 Molecular	 Mechanisms	Modulating	 the	
Phenotype	of	Macrophages	and	Microglia.	Front	Immunol	8,	1520.	
Arnold,	 L.,	 Henry,	 A.,	 Poron,	 F.,	 Baba-Amer,	 Y.,	 van	 Rooijen,	 N.,	 Plonquet,	 A.,	 Gherardi,	 R.K.,	 and	
Chazaud,	 B.	 (2007).	 Inflammatory	 monocytes	 recruited	 after	 skeletal	 muscle	 injury	 switch	 into	
antiinflammatory	macrophages	 to	support	myogenesis.	The	 Journal	of	experimental	medicine	204,	
1057-1069.	
Bizzarro,	 V.,	 Belvedere,	 R.,	 Dal	 Piaz,	 F.,	 Parente,	 L.,	 and	 Petrella,	 A.	 (2012).	 Annexin	 A1	 induces	
skeletal	muscle	cell	migration	acting	through	formyl	peptide	receptors.	PLoS	One	7,	e48246.	
Chan,	K.L.,	Pillon,	N.J.,	Sivaloganathan,	D.M.,	Costford,	S.R.,	Liu,	Z.,	Theret,	M.,	Chazaud,	B.,	and	Klip,	
A.	 (2015).	 Palmitoleate	 Reverses	 High	 Fat-induced	 Proinflammatory	 Macrophage	 Polarization	 via	
AMP-activated	Protein	Kinase	(AMPK).	The	Journal	of	biological	chemistry	290,	16979-16988.	
d'Albis,	A.,	Couteaux,	R.,	Janmot,	C.,	Roulet,	A.,	and	Mira,	J.C.	(1988).	Regeneration	after	cardiotoxin	
















Gobbetti,	 T.,	 Coldewey,	 S.M.,	 Chen,	 J.,	 McArthur,	 S.,	 le	 Faouder,	 P.,	 Cenac,	 N.,	 Flower,	 R.J.,	




M.,	 Morris,	 J.F.,	 Buckingham,	 J.C.,	 et	 al.	 (2003).	 Aberrant	 inflammation	 and	 resistance	 to	
glucocorticoids	in	annexin	1-/-	mouse.	FASEB	J	17,	253-255.	
Jha,	A.K.,	Huang,	S.C.,	Sergushichev,	A.,	Lampropoulou,	V.,	Ivanova,	Y.,	Loginicheva,	E.,	Chmielewski,	
K.,	 Stewart,	K.M.,	Ashall,	 J.,	 Everts,	B.,	 et	al.	 (2015).	Network	 integration	of	parallel	metabolic	and	
transcriptional	data	reveals	metabolic	modules	that	regulate	macrophage	polarization.	Immunity	42,	
419-430.	
Jorgensen,	 S.B.,	 Wojtaszewski,	 J.F.,	 Viollet,	 B.,	 Andreelli,	 F.,	 Birk,	 J.B.,	 Hellsten,	 Y.,	 Schjerling,	 P.,	
Vaulont,	 S.,	 Neufer,	 P.D.,	 Richter,	 E.A.,	 et	 al.	 (2005).	 Effects	 of	 alpha-AMPK	 knockout	 on	 exercise-
induced	gene	activation	in	mouse	skeletal	muscle.	FASEB	J	19,	1146-1148.	
Kjobsted,	 R.,	 Hingst,	 J.R.,	 Fentz,	 J.,	 Foretz,	 M.,	 Sanz,	 M.N.,	 Pehmoller,	 C.,	 Shum,	M.,	 Marette,	 A.,	
Mounier,	R.,	Treebak,	J.T.,	et	al.	(2018).	AMPK	in	skeletal	muscle	function	and	metabolism.	FASEB	J	
32,	1741-1777.	
Lantier,	 L.,	 Fentz,	 J.,	 Mounier,	 R.,	 Leclerc,	 J.,	 Treebak,	 J.T.,	 Pehmoller,	 C.,	 Sanz,	 N.,	 Sakakibara,	 I.,	
Saint-Amand,	 E.,	 Rimbaud,	 S.,	 et	 al.	 (2014).	 AMPK	 controls	 exercise	 endurance,	 mitochondrial	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.




Lantier,	 L.,	 Mounier,	 R.,	 Leclerc,	 J.,	 Pende,	 M.,	 Foretz,	 M.,	 and	 Viollet,	 B.	 (2010).	 Coordinated	




















Moraes,	 L.A.,	 Kar,	 S.,	 Foo,	 S.L.,	 Gu,	 T.,	 Toh,	 Y.Q.,	 Ampomah,	 P.B.,	 Sachaphibulkij,	 K.,	 Yap,	 G.,	
Zharkova,	O.,	Lukman,	H.M.,	et	al.	(2017).	Annexin-A1	enhances	breast	cancer	growth	and	migration	
by	 promoting	 alternative	 macrophage	 polarization	 in	 the	 tumour	 microenvironment.	 Sci	 Rep	 7,	
17925.	
Motwani,	 M.P.,	 and	 Gilroy,	 D.W.	 (2015).	 Macrophage	 development	 and	 polarization	 in	 chronic	
inflammation.	Semin	Immunol	27,	257-266.	
Mounier,	R.,	 Lantier,	 L.,	 Leclerc,	 J.,	Sotiropoulos,	A.,	Foretz,	M.,	and	Viollet,	B.	 (2011).	Antagonistic	
control	of	muscle	cell	size	by	AMPK	and	mTORC1.	Cell	cycle	(Georgetown,	Tex	10,	2640-2646.	
Mounier,	R.,	Lantier,	L.,	Leclerc,	J.,	Sotiropoulos,	A.,	Pende,	M.,	Daegelen,	D.,	Sakamoto,	K.,	Foretz,	
M.,	 and	 Viollet,	 B.	 (2009).	 Important	 role	 for	 AMPKalpha1	 in	 limiting	 skeletal	 muscle	 cell	
hypertrophy.	 FASEB	 journal	 :	 official	 publication	 of	 the	 Federation	 of	 American	 Societies	 for	
Experimental	Biology	23,	2264-2273.	
Mounier,	 R.,	 Theret,	 M.,	 Arnold,	 L.,	 Cuvellier,	 S.,	 Bultot,	 L.,	 Goransson,	 O.,	 Sanz,	 N.,	 Ferry,	 A.,	
Sakamoto,	K.,	Foretz,	M.,	et	al.	(2013).	AMPKalpha1	Regulates	Macrophage	Skewing	at	the	Time	of	
Resolution	of	Inflammation	during	Skeletal	Muscle	Regeneration.	Cell	metabolism	18,	251-264.	












All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
		 24	




Perretti,	 M.,	 Leroy,	 X.,	 Bland,	 E.J.,	 and	 Montero-Melendez,	 T.	 (2015).	 Resolution	 Pharmacology:	
Opportunities	for	Therapeutic	Innovation	in	Inflammation.	Trends	Pharmacol	Sci	36,	737-755.	
Rhys,	 H.I.,	 Dell'Accio,	 F.,	 Pitzalis,	 C.,	 Moore,	 A.,	 Norling,	 L.V.,	 and	 Perretti,	 M.	 (2018).	 Neutrophil	






interactions	 with	myogenic	 precursor	 cells	 during	 skeletal	 muscle	 regeneration.	 The	 FEBS	 journal	
280,	4118-4130.	
Saclier,	 M.,	 Yacoub-Youssef,	 H.,	 Mackey,	 A.L.,	 Arnold,	 L.,	 Ardjoune,	 H.,	 Magnan,	 M.,	 Sailhan,	 F.,	
Chelly,	J.,	Pavlath,	G.K.,	Mounier,	R.,	et	al.	(2013b).	Differentially	activated	macrophages	orchestrate	
myogenic	precursor	cell	fate	during	human	skeletal	muscle	regeneration.	Stem	Cells	31,	384-396.	
Scannell,	M.,	 Flanagan,	M.B.,	 deStefani,	 A.,	Wynne,	 K.J.,	 Cagney,	 G.,	 Godson,	 C.,	 and	Maderna,	 P.	
(2007).	Annexin-1	and	peptide	derivatives	are	released	by	apoptotic	cells	and	stimulate	phagocytosis	
of	apoptotic	neutrophils	by	macrophages.	J	Immunol	178,	4595-4605.	














Troidl,	 C.,	Mollmann,	 H.,	 Nef,	 H.,	Masseli,	 F.,	 Voss,	 S.,	 Szardien,	 S.,	Willmer,	M.,	 Rolf,	 A.,	 Rixe,	 J.,	
Troidl,	 K.,	 et	 al.	 (2009).	 Classically	 and	 alternatively	 activated	 macrophages	 contribute	 to	 tissue	
remodelling	after	myocardial	infarction.	J	Cell	Mol	Med	13,	3485-3496.	
Van	den	Bossche,	 J.,	O'Neill,	 L.A.,	and	Menon,	D.	 (2017).	Macrophage	 Immunometabolism:	Where	
Are	We	(Going)?	Trends	Immunol	38,	395-406.	
Varga,	 T.,	 Mounier,	 R.,	 Gogolak,	 P.,	 Poliska,	 S.,	 Chazaud,	 B.,	 and	 Nagy,	 L.	 (2013).	 Tissue	 LyC6-	
macrophages	are	generated	in	the	absence	of	circulating	LyC6-	monocytes	and	Nur77	in	a	model	of	
muscle	regeneration.	J	Immunol	191,	5695-5701.	




G.,	 Pintye,	 E.,	 et	 al.	 (2016b).	 Macrophage	 PPARgamma,	 a	 Lipid	 Activated	 Transcription	 Factor	
Controls	the	Growth	Factor	GDF3	and	Skeletal	Muscle	Regeneration.	Immunity	45,	1038-1051.	
	
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.















All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.












































WT / WT GFP / GFP























All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.





















All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.

























































- - + + +

























































































All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.



























All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
A B








DAPI F4/80 ANXA1 Merged
C
Supplementary Figure 1
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 








All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.










All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.















All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/375709doi: bioRxiv preprint first posted online Aug. 4, 2018; 
